Telomir Pharmaceuticals Inc [NASDAQ: TELO] jumped around 0.02 points on Monday, while shares priced at $1.42 at the close of the session, up 1.43%.
Telomir Pharmaceuticals Inc stock is now -75.43% down from its year-to-date (YTD) trading value. TELO Stock saw the intraday high of $1.42 and lowest of $1.37 per share. The company’s 52-week high price is 7.08, which means current price is +26.79% above from all time high which was touched on 03/13/25.
Compared to the average trading volume of 4.52M shares, TELO reached a trading volume of 8393932 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Telomir Pharmaceuticals Inc [TELO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TELO shares is $15.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TELO stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Rodman & Renshaw have made an estimate for Telomir Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 21, 2025.
The Price to Book ratio for the last quarter was 90.04, with the Price to Cash per share for the same quarter was set at 0.02.
How has TELO stock performed recently?
Telomir Pharmaceuticals Inc [TELO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.97. With this latest performance, TELO shares gained by 14.52% in over the last four-week period, additionally sinking by -51.54% over the last 6 months – not to mention a drop of -65.53% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TELO stock in for the last two-week period is set at 50.09, with the RSI for the last a single of trading hit 0.0827, and the three-weeks RSI is set at 0.1109 for Telomir Pharmaceuticals Inc [TELO]. The present Moving Average for the last 50 days of trading for this stock 1.4980, while it was recorded at 1.3980 for the last single week of trading, and 2.7751 for the last 200 days.
Telomir Pharmaceuticals Inc (TELO) Capital Structure & Debt Analysis
According to recent financial data for Telomir Pharmaceuticals Inc. ( TELO), the Return on Equity (ROE) stands at -1575.45%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -1101.13%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Telomir Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -3353.71%, showcasing its effectiveness in deploying capital for earnings.
Telomir Pharmaceuticals Inc (TELO) Efficiency & Liquidity Metrics
Based on Telomir Pharmaceuticals Inc’s (TELO) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Telomir Pharmaceuticals Inc (TELO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Telomir Pharmaceuticals Inc. (TELO) effectively leverages its workforce, generating an average of -$3228000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.38% and a Quick Ratio of 2.38%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Telomir Pharmaceuticals Inc [TELO]
With the latest financial reports released by the company, Telomir Pharmaceuticals Inc posted -0.17/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TELO.
Insider trade positions for Telomir Pharmaceuticals Inc [TELO]
There are presently around $8.74%, or 13.87%% of TELO stock, in the hands of institutional investors. The top three institutional holders of TELO stocks are: BLACKROCK INC. with ownership of 87899.0 shares, which is approximately 0.2969%. GEODE CAPITAL MANAGEMENT, LLC, holding 66355.0 shares of the stock with an approximate value of $$0.32 million in TELO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $$0.24 million in TELO stock with ownership which is approximately 0.1694%.
